Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Exclusion Criteria

• •GOG performance status 0-2
• •ANC ≥ 1,500/mm³
• •Platelet count ≥ 100,000/mm³
• •Creatinine ≤ 1.5 times upper limit of normal (ULN)
• •Bilirubin ≤ 1.5 times ULN
• •AST and ALT ≤ 2.5 times ULN
• •Alkaline phosphatase ≤ 2.5 times ULN
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment
• •No neuropathy (sensory and motor) \> grade 1, according to NCI CTCAE v3.0
• •No active infection requiring antibiotics (except an uncomplicated urinary tract infection)
• •No other invasive malignancies within the past 5 years except non-melanoma skin cancer
• •No prior cancer treatment that contraindicates study therapy
• •Recovered from prior surgery, radiotherapy, or chemotherapy
• •At least 1 week since prior hormonal therapy for endometrial cancer
• •At least 3 weeks since prior biological therapy, immunotherapy, or other therapy for endometrial cancer
• •At least 4 weeks since prior radiotherapy
• •More than 3 years since prior radiotherapy for localized breast cancer, head and neck cancer, or skin cancer and
• •* No recurrent or persistent breast cancer, head and neck cancer, or skin cancer
• •More than 3 years since prior adjuvant chemotherapy for localized breast cancer
• •* No recurrent or metastatic breast cancer
• •No prior radiotherapy to any portion of the abdominal cavity or pelvis except for the treatment of endometrial cancer
• •No prior chemotherapy for any abdominal or pelvic tumor except for the treatment of endometrial cancer
• •No prior gemcitabine hydrochloride